2024年，艾伯维凭借自免领域两款核心产品——IL-23单抗Skyrizi（利生奇珠单抗）和JAK1抑制剂Rinvoq（乌帕替尼）的强劲表现，成功抵消了Humira（阿达木单抗）销售额下滑的影响。全年总营收达563.34亿美元，同比增长3.7%，其中Skyrizi与Rinvoq合计贡献收入176.89亿美元，同比增速均超50%。艾伯维进一步上调2027年两款药物合并销售预期至270亿美元，较此前目 ...

Candidates should be aware that the deadline to apply for the AIIMS INICET July 2025 session is April 15, 2025, scroll down ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...

Corporation announced that the European Commission has granted marketing authorization for RYTELO as a monotherapy for the ...

Rigel Therapeutics expands oncology portfolio with REZLIDHIA & GAVRETO, sees promising R289 results. Click here to read my ...

Teleneurorehabilitation provides similar improvement in motor and nonmotor symptoms for patients with Parkinson’s disease as ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

The ongoing application process for NEET MDS 2025 will be closed today. Candidates can apply through the direct link given ...

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.